- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03478436
Pharmacokinetics of Doxycycline in Skin of Healthy Volunteers
March 20, 2018 updated by: Markus Zeitlinger, Medical University of Vienna
Pharmacokinetics of DFD-09 (Doxycycline) Capsules, 40 mg in Skin of Healthy Volunteers Under Fed and Fasting Conditions - an Exploratory Microdialysis Study
This study explored the impact of food on skin and plasma pharmacokinetics of doxycycline
Study Overview
Detailed Description
Sub-antimicrobial dose doxycycline is approved for the treatment of rosacea.
This work investigated the pharmacokinetics of doxycycline in skin and plasma of fed and fasting healthy volunteers receiving a 14-day treatment course with once daily 40 mg doxycycline.
Dermal measurements were performed by means of in vivo microdialysis.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Healthy males
- Healthy, according to the medical history, ECG, vital signs, laboratory results and physical examination as determined by the Investigator/Sub-Investigator
- Signed written informed consent prior to inclusion in the study
- 18-45 years old inclusive
- BMI: 18.5 to 30 kg/m2
- SBP: 100-139 mmHg
- DBP: 55-89 mmHg
- PR: 55-100 bpm (measured after 5 min of rest, sitting position)
- ability to comprehend the full nature and purpose of the study, including possible risks and side effects
- ability to co-operate with the Investigator and to comply with the requirements of the entire study
- availability to volunteer for the entire study duration and willing to adhere to all protocol requirements
Exclusion Criteria:
Any clinically relevant abnormalities in ECG (12 leads)
- Any clinically relevant abnormal physical findings
- Any clinically relevant abnormal laboratory values indicative of physical illness
- Ascertained or presumptive hypersensitivity to the active principle and/or formulations ingredients of the study drug or to tetracyclines in general
- History of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
- Relevant history of malignancy, of renal, hepatic, cardiovascular, respiratory, gastrointestinal, musculoskeletal, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study
- Any psychiatric illnesses
- Presence of any skin condition that would interfere with the placement of microdialysis probes
- Any dermatological drug therapy on the surface of both thighs within 14 days before study day 1 of this study
- Use of any medication(including OTC) within 1 week prior to study day 1
- Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort) within 1 month prior to study day 1
- Participation in another clinical study investigating another IMP within 1 month prior to study day 1
- Blood donations within 1 month prior to study day 1 or planned within 1 month after the last study-related blood draw
- History of drug or alcohol abuse (>2 drinks/day, defined according to USDA Dietary Guidelines 2005)
- other objections to study participation in the opinion of the Investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: fed group
14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
|
Doxycycline 40 mg capsules
|
Other: fasting group
14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
|
Doxycycline 40 mg capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-t
Time Frame: at day 14
|
mg∙h/L
|
at day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Markus Zeitlinger, Department of Clinical Pharmacology, Medical University of Vienna
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
October 25, 2016
Study Completion (Actual)
October 25, 2016
Study Registration Dates
First Submitted
March 8, 2018
First Submitted That Met QC Criteria
March 20, 2018
First Posted (Actual)
March 27, 2018
Study Record Updates
Last Update Posted (Actual)
March 27, 2018
Last Update Submitted That Met QC Criteria
March 20, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Version 1.0 / 04.05.2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
publication in peer-reviewed journal
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
Clinical Trials on Doxycycline
-
Thomas GardnerJuvenile Diabetes Research FoundationCompleted
-
University of PittsburghTu Du HospitalCompleted
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Warner ChilcottCompletedAcne VulgarisUnited States
-
PfizerCompleted
-
Warner ChilcottCompleted
-
Samsung Medical CenterCompleted
-
Chinese University of Hong KongNot yet recruitingChlamydia | Gonorrhea | Sexually Transmitted Diseases, Bacterial | SyphilisHong Kong
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaCompleted
-
Aljazeera HospitalUnknown